Johnson & Johnson is acquiring all outstanding shares of Abiomed for $16.6 billion, the company announced Tuesday. The deal has been unanimously approved by the boards of directors of both companies. J&J will acquire all outstanding shares of Abiomed for $380 per share, which it plans to finance through a combination of cash and debt. Both companies expect to close the acquisition early next year. Under the terms of the agreement, Abiomed shareholders will be offered a one-time, non-tradeable contingent value right (CVR). This will entitle all stockholders to up to $35 more per share in cash, contingent upon the achievement of several clinical and commercial milestones. These milestones include reaching net sales for Abiomed products exceeding $3.7 billion during J&J
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!